Cyclobenzaprine

Cyclobenzaprine (MK130) is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Cyclobenzaprine also possesses antiparasitic activity. Cyclobenzaprine holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases[1][2][3][4][5].

Product Specifications

CAS Number

[303-53-7]

Product Name Alternative

MK130

UNSPSC

12352005

Target

5-HT Receptor; Parasite

Related Pathways

Anti-infection; GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Infection; Neurological Disease

Smiles

CN(C)CC/C=C1C2=C(C=CC=C2)C=CC3=C/1C=CC=C3

Molecular Formula

C20H21N

Molecular Weight

275.39

References & Citations

[1]Khan I, et al. 2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL) : StatPearls Publishing; 2025 Jan–.|[2]Honda, M., T. Nishida, and H. Ono, Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT (2) receptors. Eur J Pharmacol, 2003. 458 (1-2) : p. 91-9.|[3]Borenstein D G & Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials[J]. Clinical therapeutics, 2003, 25 (4) : 1056-1073.|[4]Share N N, et al. Cyclobenzaprine: a novel centrally acting skeletal muscle relaxant[J]. Neuropharmacology, 1975, 14 (9) : 675-684.|[5]Cunha-Júnior EF, et al. Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice. PLoS Negl Trop Dis. 2017 Jan 3;11 (1) :e0005281. |[6]Kobayashi, H., Y. Hasegawa, and H. Ono, Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol, 1996. 311 (1) : p. 29-35.